Citius Pharma up on submitting marketing application for blood disorder drug

Citius Pharmaceuticals

28/09/2022 14:55

** Drug developer Citius Pharmaceuticals Inc's shares
 CTXR.O  rise 4.2% to $1.22 
    ** Co submits its first marketing application to U.S. FDA
for its drug to treat patients with persistent or recurrent
cutaneous T-cell lymphoma 
    ** Cutaneous T-cell lymphoma is a type of rare blood
disorder in which infection fighting cells develop abnormalities
leading them to attack ones own skin cell 
    ** Up to Tuesday's close, stock had lost ~23% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))